Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)

NCT02959489 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT02959489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02959489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)
Lead sponsor
Brigham and Women's Hospital
Phase
Not applicable
Overall status
Completed
Start date
November 30, 2016
Completion date
April 29, 2021
Enrollment
315 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, amyloid beta-peptides, education, neuroimaging, neuropsychological tests, risk assessment